Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unable to cope with the below par performance of its over-the-counter (OTC) segment, US-based Quigley, the maker of lozenges, gums and sugar free tablets for common cold, is looking at various strategic options, including selling of its pharmaceutical division.
Subscribe to our email newsletter
In addition to implementing cost cutting measures, particularly in the area of executive compensation and other operating areas, the company is also contemplating the separation of its OTC products and pharmaceutical assets.
The company in a statement said: “cost reduction has become necessary due to reduced performance of the company’s OTC segment of the business which is reflective of the broad downturn in consumer spending on this category of goods.”
Quigley Corporation is a Natural Health Medical Science company that manufactures and markets cold remedy brands through its over-the-counter consumer healthcare segment, and is developing potential ethical pharmaceutical products through its subsidiary, Quigley Pharma Inc.